Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Consensus rating of moderate Buy based on 7 analyst reviews.
  • Average 12-month target price stands at USD 28.79.
  • Latest quarter EPS of -0.36 beats estimate by USD 0.03; revenue rose 5.6% year-over-year.

NovoCure Limited (NASDAQ: NVCR), a medical equipment company specializing in tumor treating fields (TTFields) devices for solid tumor cancers, currently holds a consensus analyst rating of "Moderate Buy," according to MarketBeat Ratings. This consensus is derived from seven analysts covering the stock, with four recommending a buy and three recommending a hold.

The average 12-month target price set by analysts over the past year is approximately USD 28.79. This target reflects a range of recent analyst opinions and price adjustments.

Several recent reports illustrate varying views on NovoCure’s valuation. Wells Fargo & Company maintained an "equal weight" rating but revised their price target downward to USD 14.50 from USD 40.00 in late July. Conversely, Piper Sandler reaffirmed an "overweight" rating with a target price of USD 34.00 in late June. Additionally, LADENBURG THALM/SH SH initiated coverage in early July with a "buy" rating and a USD 30.00 price target.

NovoCure reported its latest quarterly earnings on July 24th, posting a loss of USD 0.36 per share, which was slightly better than the consensus estimate of a USD 0.39 loss. The company recorded revenue of USD 158.80 million, surpassing analyst estimates of USD 153.87 million, representing a 5.6% increase compared to the same quarter last year.

Financial metrics show that NovoCure continues to operate with a negative return on equity of 47.74% and a net margin of -27.13%. Analysts currently project an EPS of -1.30 for the current fiscal year, indicating continued losses.

NovoCure operates internationally, offering products such as Optune Gio and Optune Lua, used in the treatment of solid tumors across markets including the United States, Germany, Japan, and Greater China.